Arsanis Biosciences GmbH, a biotechnology company developing anti-infective human monoclonal antibodies, achieved a major milestone by nominating the preclinical development candidates for its lead program, a monoclonal antibody cocktail to prevent and treat severe hospital associated S. aureus infections. 

View Document